Baseline MRI PI-RADS Linked to Biopsy Reclassification in Prostate Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 14, 2024 -- The baseline magnetic resonance imaging (MRI) Prostate Imaging Reporting and Data System (PI-RADS) score is associated with biopsy reclassification among men with prostate cancer undergoing active surveillance (AS), according to a study published online June 25 in The Journal of Urology.
Kiran R. Nandalur, M.D., from William Beaumont University Hospital in Royal Oak, Michigan, and colleagues identified men in the Michigan Urological Surgery Improvement Collaborative registry with National Comprehensive Cancer Network (NCCN) low-risk and favorable intermediate-risk prostate cancer who underwent MRI within six months before or after initial biopsy and enrolled in AS. Data were included for 1,491 men with a median age of 64 years and median follow-up of 11.0 months after a landmark time of six months from diagnostic biopsy.
The researchers found associations with an increased risk for biopsy reclassification for baseline PI-RADS ≥4 lesions, grade group 2 versus 1, and increasing age (per 10 years; hazard ratios, 2.3, 2.5, and 1.8, respectively). There was no significant interaction observed between NCCN risk group and MRI findings.
"Clinical implications include improved upfront AS risk stratification with MRI, particularly important in the NCCN favorable intermediate-risk group, along with tailoring intensity of surveillance," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.